Evidence map›Paper›PMID 32601160›Full record

ArticleAntimicrobial agents and chemotherapy2020

Prolonged Exposure to β-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin.

Rachel E Jenson, Sarah L Baines, Benjamin P Howden, Nagendra N Mishra, Sabrina Farah, Cassandra Lew, Andrew D Berti, Sanjay K Shukla, Arnold S Bayer, Warren E Rose

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. β-Lactam Adjunctive Therapy Compared to Vancomycin or Daptomycin Monotherapy in Adult Patients With Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  4. Article
  5. Review
  6. Antimicrobial agents and chemotherapy · 2023
    Article
  7. Article
  8. Article
  9. The Role ofAntimicrobial agents and chemotherapy · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Adjunctive β-lactams forTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Rachel E JensonSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sarah L BainesDoherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-0557-0518
Benjamin P HowdenDoherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0003-0237-1473
Nagendra N MishraThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Sabrina FarahThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Cassandra LewSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Andrew D BertiSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sanjay K ShuklaMarshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
Arnold S BayerThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Warren E RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA warren.rose@wisc.edu.ORCID 0000-0001-5012-5993
University of Wisconsin–Madison · USUniversity of California, Los Angeles · USThe University of Melbourne · AUMarshfield Clinic · US

Funding

Mechanisms and use of penicillin-binding protein inhibition to optimize cationic peptide anti-MRSA treatmentR01AI132627 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ROSE, WARREN E · 2017 to 2021
$2.1M
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical TranslatabilityR01AI146078 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
$1.9M
NIAID NIH HHS R01 AI132627NIAID NIH HHS R01 AI146078
6 · The paper itself

Abstract

Daptomycin-nonsusceptible (DAP-NS)

Indexed as

DaptomycinMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsBacterial Proteinsbeta-LactamsMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsBacterial Proteinsbeta-LactamsDaptomycincationic peptidemethicillin-resistant Staphylococcus aureusmprFpenicillin-binding protein

Identifiers

PMID32601160
PMCPMC7449200
OpenAlexW3037854724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.